文献速递神经核医学肿瘤 PET/CT

基于18F-DOPA PET/CT的转移性神经内分泌肿瘤病灶间异质性

Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT.
PubMed 文献 · Clin Nucl Med · 2019-01-01

该回顾性观察研究分析了38例小肠神经内分泌肿瘤患者的18F-DOPA PET/CT,以病灶SUVpeak与背景器官SUVmean比值计算摄取,发现患者内病灶间F-DOPA摄取中位差异达8倍至44倍,并在部分患者中识别出摄取轻度或极度升高的病灶。

要点

  • 患者内不同病灶间F-DOPA摄取差异中位达8倍至44倍
  • 20例可评估患者中12例存在轻度高摄取病灶,5例存在极度高摄取病灶
  • 病灶间摄取异质性提示可筛选高活性病灶用于局部治疗

核心结论

  • F-DOPA PET显示肿瘤病灶间F-DOPA摄取存在显著异质性,并可在患者内识别出轻度或极度高F-DOPA摄取的病灶。

研究设计与样本

  • 回顾性观察研究,纳入38例小肠神经内分泌肿瘤患者,共检测680余个病灶,其中35例为5-羟色胺分泌型。

主要发现

  • 患者内病灶间F-DOPA摄取差异中位为8倍,最高达44倍。
  • 20例可评估患者中,12例发现轻度高F-DOPA摄取病灶,5例发现极度高F-DOPA摄取病灶。

关键数值与推荐

  • F-DOPA摄取以病灶SUVpeak除以背景器官SUVmean计算。
  • 患者内异质性程度以最高摄取病灶除以最低摄取病灶计算。
  • 高于第三四分位数1.5倍四分位距以上定义为轻度高摄取,高于3倍四分位距以上定义为极度高摄取。
  • 仅在病灶数≥10的患者中评估轻度或极度高摄取病灶的存在。

临床怎么用

  • 可利用F-DOPA PET/CT评估患者内病灶摄取异质性,筛选高活性病灶用于局部治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Neuroendocrine tumors (NETs) can produce neuroendocrine amines resulting in symptoms. Selecting the most active amine-producing tumor lesions for local treatment might be beneficial for patients with metastatic small intestinal NET. Tumor burden correlates with catecholamine pathway activity. We analyzed interlesional heterogeneity with F-DOPA PET scans in patients with small intestinal NET and investigated if lesions with substantially higher F-DOPA uptake could be identified. METHODS: In this retrospective, observational study, the F-DOPA uptake was calculated by dividing SUVpeak of the lesion by the SUVmean of the background organ. The magnitude of heterogeneity between lesions within a patient was calculated by dividing the lesion with the highest by the one with the lowest F-DOPA uptake. Lesions with a higher F-DOPA uptake than the upper inner or outer fence (>1.5 or 3 times the interquartile range above the third quartile) were defined as lesions with mild or extreme high F-DOPA uptake, respectively, and presence of these was determined in patients with 10 lesions or more. RESULTS: F-DOPA was detected over 680 lesions in 38 patients, of which 35 were serotonin producing. F-DOPA uptake varied with a median of 8-fold up to 44-fold between lesions within a patient. In 12 of 20 evaluable patients, lesions with mild high F-DOPA uptake were found, and in 5, lesions with extreme high F-DOPA uptake. CONCLUSIONS: F-DOPA-PET showed considerable heterogeneity in F-DOPA uptake between tumor lesions and identified lesions within patients with mild or extreme high F-DOPA uptake.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. de Hosson LD, van der Loo-van der Schaaf AM, Boellaard R, et al. Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT. Clin Nucl Med. 2019. PMID: 31274606. doi:10.1097/RLU.0000000000002640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。